Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trialKazumoto Iijima, Yasuo Ohashi, Mayumi Sako et al.|The Lancet|2014Cited by 450
A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatmentNorishige Yoshikawa, Kazumoto Iijima, Koichi Nakanishi et al.|Kidney International|2014Cited by 135
Long-Term Results of a Randomized Controlled Trial in Childhood IgA NephropathyKoichi Kamei, Norishige Yoshikawa, Koichi Nakanishi et al.|Clinical Journal of the American Society of Nephrology|2011Cited by 98
Rituximab therapy for refractory steroid-resistant nephrotic syndrome in childrenKoichi Kamei, Kazumoto Iijima, Kandai Nozu et al.|Pediatric Nephrology|2018Cited by 63
Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic SyndromeKazumoto Iijima, Mayumi Sako, Mari S. Oba et al.|Institutional Repositories DataBase (IRDB)|2022Cited by 57